Related references
Note: Only part of the references are listed.Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8
W. Yan et al.
ONCOGENE (2013)
Global Cancer Statistics
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
NDRG1 as a biomarker for metastasis, recurrence and of poor prognosis in hepatocellular carcinoma
Jun Cheng et al.
CANCER LETTERS (2011)
Mitochondria in Apoptosis: Bcl-2 Family Members and Mitochondrial Dynamics
Jean-Claude Martinou et al.
DEVELOPMENTAL CELL (2011)
Mitochondrial signaling in cell death via the Bcl-2 family
Brian Leibowitz et al.
CANCER BIOLOGY & THERAPY (2010)
Targeting the p53 Pathway of Apoptosis
Joana D. Amaral et al.
CURRENT PHARMACEUTICAL DESIGN (2010)
Identification of Histone Deacetylase 3 as a Biomarker for Tumor Recurrence Following Liver Transplantation in HBV-Associated Hepatocellular Carcinoma
Li-Ming Wu et al.
PLOS ONE (2010)
Histone Deacetylase 8 in Neuroblastoma Tumorigenesis
Ina Oehme et al.
CLINICAL CANCER RESEARCH (2009)
p53-Induced Apoptosis and Inhibitors of p53
Surendra Kumar Nayak et al.
CURRENT MEDICINAL CHEMISTRY (2009)
Histone Deacetylase Inhibitors: Potential in Cancer Therapy
P. A. Marks et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2009)
Predictive Value of Expression and Promoter Hypermethylation of XAF1 in Hepatitis B Virus-Associated Hepatocellular Carcinoma Treated with Transplantation
Feng Zhang et al.
ANNALS OF SURGICAL ONCOLOGY (2008)
Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer
Florian R. Fritzsche et al.
BMC CANCER (2008)
Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy
W. Weichert et al.
BRITISH JOURNAL OF CANCER (2008)
Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer:: Specific role of class I histone deacetylases in vitro and in vivo
Wilko Weichert et al.
CLINICAL CANCER RESEARCH (2008)
Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer:: a retrospective analysis
Wilko Weichert et al.
LANCET ONCOLOGY (2008)
Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas
Wilko Weichert et al.
NEOPLASIA (2008)
Histone deacetylases and cancer
M. A. Glozak et al.
ONCOGENE (2007)
Connected to death: The (unexpurgated) mitochondrial pathway of apoptosis
D Spierings et al.
SCIENCE (2005)
Histone deacetylase inhibitors differentially stabilize acetylated p53 and induce cell cycle arrest or apoptosis in prostate cancer cells
S Roy et al.
CELL DEATH AND DIFFERENTIATION (2005)
Histone deacetylase-1 and-3 protein expression in human breast cancer:: a tissue microarray analysis
CA Krusche et al.
BREAST CANCER RESEARCH AND TREATMENT (2005)
Loss of Gelsolin expression in human ovarian carcinomas
A Noske et al.
EUROPEAN JOURNAL OF CANCER (2005)
Apoptosis pathways in cancer and cancer therapy
KM Debatin
CANCER IMMUNOLOGY IMMUNOTHERAPY (2004)
Expression of histone deacetylase 8, a class I histone deacetylase, is restricted to cells showing smooth muscle differentiation in normal human tissues
D Waltregny et al.
AMERICAN JOURNAL OF PATHOLOGY (2004)
Control of apoptosis by p53
JS Fridman et al.
ONCOGENE (2003)
The outcome of liver transplantation in patients with hepatocellular carcinoma in the united states between 1987 and 2001: 5-year survival has improved significantly with time
HY Yoo et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
14-3-3 proteins and survival kinases cooperate to inactivate BAD by BH3 domain phosphorylation
SR Datta et al.
MOLECULAR CELL (2000)
Primary prevention of hepatocellular carcinoma in developing countries
CP Wild et al.
MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH (2000)
Share Paper
